Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-071339
Filing Date
2025-05-14
Accepted
2025-05-14 16:00:27
Documents
81
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q klrs-20250331.htm   iXBRL 10-Q 2646831
2 EX-10.3 klrs-ex10_3.htm EX-10.3 126091
3 EX-10.4 klrs-ex10_4.htm EX-10.4 111302
4 EX-10.5 klrs-ex10_5.htm EX-10.5 641112
5 EX-10.6 klrs-ex10_6.htm EX-10.6 350332
6 EX-10.7 klrs-ex10_7.htm EX-10.7 21834
7 EX-31.1 klrs-ex31_1.htm EX-31.1 17885
8 EX-31.2 klrs-ex31_2.htm EX-31.2 17812
9 EX-32.1 klrs-ex32_1.htm EX-32.1 9449
10 EX-32.2 klrs-ex32_2.htm EX-32.2 9430
  Complete submission text file 0000950170-25-071339.txt   11601613

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT klrs-20250331.xsd EX-101.SCH 1491254
84 EXTRACTED XBRL INSTANCE DOCUMENT klrs-20250331_htm.xml XML 1547157
Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Filer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39409 | Film No.: 25945069
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)